-+ 0.00%
-+ 0.00%
-+ 0.00%

ACTUATE THERAPEUTICS’ ELRAGLUSIB SELECTED FOR EVALUATION IN BEACON2 TRIAL FOR HIGH-RISK PEDIATRIC NEUROBLASTOMA

Reuters·06/09/2026 11:45:33

Please log in to view news